CTMX FY 2021 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M-45.5% YoY

Gross Profit

$37M100.0% margin

Operating Income

-$116M-311.0% margin

Net Income

-$116M-310.5% margin

EPS (Diluted)

$-1.26

Cash Flow

Operating Cash Flow

-$119M

Free Cash Flow

-$121M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$339M

Total Liabilities

$340M

Stockholders' Equity

-$459,000

Cash & Equivalents

$206M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$68M	-45.5%
Gross Profit	$37M	$68M	-45.5%
Operating Income	-$116M	-$81M	-44.1%
Net Income	-$116M	-$65M	-78.8%